ImmunityBio (IBRX) saw its share prices jump by 14.55% as investors anticipated its participation in the 2026 ASCO Genitourinary Cancers Symposium. The company is also expanding its cancer treatment, Anktiva, into Saudi Arabia for lung cancer patients after securing FDA approval there, expecting a significant sales jump.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
ImmunityBio (IBRX) Jumps Ahead of Oncology Event
ImmunityBio (IBRX) saw its share prices jump by 14.55% as investors anticipated its participation in the 2026 ASCO Genitourinary Cancers Symposium. The company is also expanding its cancer treatment, Anktiva, into Saudi Arabia for lung cancer patients after securing FDA approval there, expecting a significant sales jump.